Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
49,844,823
-
Shares change
-
+10,774,719
-
Total reported value, excl. options
-
$84,098,555
-
Value change
-
+$17,530,681
-
Put/Call ratio
-
131%
-
Number of buys
-
61
-
Number of sells
-
-38
-
Price
-
$1.69
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q3 2023
152 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49,844,823 shares
of 1,079,784,035 outstanding shares and own 4.6% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (14,675,687 shares), BlackRock Inc. (10,811,031 shares), ARMISTICE CAPITAL, LLC (3,476,000 shares), GEODE CAPITAL MANAGEMENT, LLC (2,806,183 shares), STATE STREET CORP (2,719,592 shares), CREDIT SUISSE AG/ (1,534,137 shares), JPMORGAN CHASE & CO (1,448,432 shares), NORTHERN TRUST CORP (1,152,757 shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (1,049,934 shares), and NATIONAL BANK OF CANADA /FI/ (699,300 shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.